Medicines for Europe has expressed shock at the “concerted efforts” of some Member States to water down the Critical Medicines Act (CMA).
 
Recent debates at European Parliament committees have exposed concerns about CMA, including claims that the legislation may violate national competence. Medicines for Europe, which represents off-patent drugmakers, pushed back against the claims, arguing that CMA “would only require Member States to fully comply with existing legal obligations” and pleading with the European Council to rethink its stance.
 
The trade group said the legislation must ensure that demand side measures support viable investments in manufacturing and supply chain resilience while also supporting critical generic producers through substantial EU funding and new state aid flexibilities

[Press release Medicines for Europe]